The World Health Assembly (WHA) is the decision-making body of the WHO. The 79th meeting of the WHA was held from May 18 to May 23, 2026, in Geneva, Switzerland. Policies and decisions are largely debated and approved through two…
The post KEI Statements as Delivered at the 79th World Health Assembly appeared first on Knowledge Ecology International.
]]>On May 20, 2026, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) National Cancer Institute (NCI) regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered Cell Therapies for the Treatment…
The post KEI Comments on NIH Exclusive License to OncoVanta for Cell Therapies for Cancer appeared first on Knowledge Ecology International.
]]>On April 20, 2026, Knowledge Ecology International (KEI) submitted comments to the NIH regarding the “Prospective Grant of an Exclusive Patent License: Pigment Epithelium-Derived Factor (PEDF) Peptides and Use for Treating Retinal Degeneration” (91 FR 16205) to Perpetual Biosciences, Inc.…
The post KEI Comments on NIH Prospective License to Perpetual Biosciences appeared first on Knowledge Ecology International.
]]>On March 2, 2026, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: In Vivo Manufactured Anti-CD19 Chimeric Antigen Receptor (CAR) Products for the Treatment or Prevention…
The post KEI Comments on Exclusive License to Kyverna Therapeutics appeared first on Knowledge Ecology International.
]]>On October 20, 2025, Knowledge Ecology International (KEI) submitted comments to the NIH in response to the Federal Register notice titled, “Prospective Grant of an Exclusive Patent License: Substituted Quinoline Analogs As Aldehyde Dehydrogenase 1A1 Inhibitors” (90 FR 47782) The…
The post KEI Comments on Exclusive License to Stage One Immunotherapeutics appeared first on Knowledge Ecology International.
]]>On October 14, 2025, Knowledge Ecology International (KEI) provided the NIH with comments regarding the “Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Development of Zika Virus Strains for Use in Oncolytic Therapy” (90 FR 46414) to Advocate Aurora Research…
The post KEI Comments on Exclusive License of Zika Strain to AARI appeared first on Knowledge Ecology International.
]]>On September 24, 2025, Knowledge Ecology International submitted comments to the NIH regarding the “Prospective Grant of an NCI Exclusive Patent License: Use of Anti-Mesothelin Immunotoxins for the Treatment of Mesothelin-Expressing Cancers” (90 FR 43617) to Lysin Therapeutics. Although the…
The post KEI Comments to the NIH on Exclusive License to Lysin Therapeutics appeared first on Knowledge Ecology International.
]]>Below is a short note on good news on a court case in India concerning access to risdiplam, a treatment for spinal muscular atrophy (SMA). The note is followed by a statement on the case by Third World Network (TWN),…
The post Delhi High Court Rejects Roche’s Appeal, Paving Way for Affordable Generic Risdiplam appeared first on Knowledge Ecology International.
]]>On July 28, 2025, Knowledge Ecology International (KEI) submitted a Freedom of Information Act request for records concerning the Food and Drug Administration (FDA) Orphan Products Grant Program. The program (administered by the FDA’s Office of Orphan Products Development (OOPD))…
The post KEI Submits FOIA Regarding FDA Orphan Products Grant Program appeared first on Knowledge Ecology International.
]]>On June 2, 2025, Knowledge Ecology International (KEI) offered comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: c-Abl Tyrosine Kinase Inhibitory Compound Embodiments and Methods of Making and Using the Same”…
The post KEI Comments on NIH Exclusive License to Neurala for Central Nervous System Disorders appeared first on Knowledge Ecology International.
]]>